Despite the fact that none of the drugs were tested on any ccRCC cell lines, connectivity mapping of the tumour sample signatures (but not the group or subtype signatures) does reveal significant negative enrichment for 2 out of the 3 mTOR-inhibitors used against ccRCC (sirolimus and temsirolimus). The gene discussed is MTOR; the disease is neoplasm.